GlassScriptVio3/Apc3/Erbecryo2
Payments companies reported to CMS as associated with Vio3/Apc3/Erbecryo2. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vio3/Apc3/Erbecryo2, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vio3/Apc3/Erbecryo2
These are the largest totals companies reported as associated with Vio3/Apc3/Erbecryo2. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Diana Espinoza Barrera | Boston, MA | Critical Care Medicine (Internal Medicine) | $111.49 |
| Kai Swenson | Boston, MA | Pulmonary Disease | $111.49 |
| Adnan Majid | Boston, MA | Pulmonary Disease | $111.49 |
| Mihir Parikh | Boston, MA | Internal Medicine | $111.49 |
| Raymond Parrish | Aurora, CO | Pulmonary Disease | $111.49 |
Prescribed Vio3/Apc3/Erbecryo2?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.